A small number of people who are infected with HIV-1 produce very special antibodies. These antibodies do not just fight one virus strain, but neutralize almost all known virus strains. Research into developing an HIV vaccine focuses on discovering the factors responsible for the production of such antibodies.
A research team has been searching for these factors for years. Several have already been identified: For example, the virus load and the diversity of the viruses, the duration of the infection, and the ethnicity of the affected person can all influence the body's immune response. "In our new study, we were able to identify another factor: The genome of the HI virus," says the senior author.
The starting point for the researchers was the data and biobanked blood samples of around 4,500 HIV-infected people, recorded in the Swiss HIV Cohort Study and the Zurich Primary HIV Infection Study. In total the researchers found 303 potential transmission pairs - i.e. pairs of patients for whom the similarity of the viruses' genomic RNA indicated that they were probably infected with the same virus strain. "By comparing the immune response of these pairs of patients, we were able to show that the HI virus itself has an influence on the extent and specificity of the antibody reactions," explains the study's first author.
Antibodies acting against HIV bind to proteins found on the surface of the virus. These envelope proteins differ according to virus strain and subtype. The researchers therefore examined more closely a patient pair with very similar virus genomes and at the same time very strong activity of broadly neutralizing antibodies. "We discovered that there must be a special envelope protein that causes an efficient defense," explains another author.
In order to be able to develop an effective vaccine against HIV-1, it is necessary to pinpoint the envelope proteins and virus strains that lead to the formation of broadly acting antibodies. It is therefore planned to widen the search. "We have found one candidate. Based on that, we now want to begin developing an immunogen ourselves," adds the author.
http://www.media.uzh.ch/en/Press-Releases/2018/HIV-Vaccine.html
https://www.nature.com/articles/s41586-018-0517-0
Latest News
Mechanism of sugar signalin…
By newseditor
Posted 19 May
How does the brain turn wav…
By newseditor
Posted 19 May
A trial HIV vaccine trigger…
By newseditor
Posted 19 May
AI to predict DNA methylati…
By newseditor
Posted 19 May
Hyperactive platelets from…
By newseditor
Posted 19 May
Other Top Stories
Understanding workings of Parkinson's linked proteins
Read more
Human brains transmit information via multiple parallel pathways
Read more
New coding mechanism that transfers information from perception to…
Read more
Soft robotic apparel to avert freezing of gait in Parkinson's disease
Read more
A NICER approach to genome editing
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Molecular mechanism of treh…
By newseditor
Posted 19 May
Hue selectivity from recurr…
By newseditor
Posted 19 May
Vaccine induction of hetero…
By newseditor
Posted 19 May
Brain border-associated mac…
By newseditor
Posted 19 May
Inhibition of fatty acid up…
By newseditor
Posted 19 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar